跳至主要内容
临床试验/NL-OMON52769
NL-OMON52769
招募中
不适用

Medium and long term outcomes after modern radiotherapy for IDH mutated glioma - Radiotherapy in IDH mutated Glioma: Evaluation of Late outcomes (RIGEL)

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 79 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
Erasmus MC, Universitair Medisch Centrum Rotterdam
入组人数
79
状态
招募中
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Observational non invasive

研究者

入排标准

入选标准

  • \- Age \> 18 years
  • \- Resection (any grade) or biopsy of one of the following: glioma, WHO grade 2
  • or 3, IDH mutated
  • \- Indication and fit for standard treatment with radiotherapy and chemotherapy
  • o For WHO grade 2 tumors 50\.4 Gy (RBE) in 28 fractions.
  • o For WHO grade 3 tumors 59\.4 Gy (RBE) in 33 fractions.
  • \- Ability to comply with the protocol, including neuropsychological testing and
  • imaging, as judged by the local investigator.
  • \- Ability to understand the requirements of the study and to give written
  • informed consent.

排除标准

  • \- Any prior cranial radiotherapy.
  • \- Prior or second invasive malignancy, except non\-melanoma skin cancer,
  • completely resected cervical or prostate cancer (with PSA of less than or equal
  • to 0\.1 ng/mL).
  • \- Extensive white matter disease visible on pre\-therapy imaging (Fazekas grade
  • \- Contra\-indication for MR imaging (i.e. metal implants, claustrophobia)
  • \- Any psychological, familial, sociological or geographical condition
  • potentially hampering compliance with the study protocol and follow\-up schedule
  • in the participating hospitals
  • \- Any other serious medical condition that could interfere with follow\-up.

结局指标

主要结局

未指定

相似试验